Antitumor AZA-anthrapyrazoles: Biophysical and biochemical studies on 8- and 9-aza regioisomers

Biochemical Pharmacology

Volumn 67, Issue 4, 2004, Pages 631-642

  Sissi, Claudia ^a   Leo, Elisabetta ^a   Moro, Stefano ^a   Capranico, Giovanni ^b   Mancia, Annalaura ^b   Menta, Ernesto ^c   Krapcho, A Paul ^d   Palumbo, Manlio ^a  

^a UNIVERSITY OF PADOVA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

^c Novuspharma SpA   (Italy)

^d UNIVERSITY OF VERMONT   (United States)

Author keywords

AZA APs; DNA binder; Regioisomers; Topoisomerase II

Indexed keywords

ANTHRAQUINONE DERIVATIVE; DNA TOPOISOMERASE (ATP HYDROLYSING); LOSOXANTRONE; MITOXANTRONE;

ARTICLE; BINDING AFFINITY; DNA BINDING; DNA CLEAVAGE; DNA PURIFICATION; DNA SEQUENCE; ENZYME ACTIVITY; ENZYME SPECIFICITY; INTERMETHOD COMPARISON; LIPID SOLUBILITY; METASTASIS INHIBITION; MOLECULAR RECOGNITION; MOLECULAR SIZE; OXIDATION REDUCTION REACTION; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; PROTEIN FAMILY; PROTEIN MOTIF; PROTON TRANSPORT;

EID: 1642493662     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2003.09.035     Document Type: Article

References (30)

1. Krapcho A.P., Maresch M.J., Hacker M.P., Hazelhurst L., Menta E., Spinelli S., Beggiolin G., Giuliani F.C., Pezzoni P., Tognella S. Anthracene-9,10-diones and aza bioisosteres as antitumor agents. Curr. Med. Chem. 2:1995;803-824.
2. Faulds D., Balfour J.A., Chrisp P., Langtry H.D. Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer. Drugs. 41:1991;400-449.
3. Palumbo M, Gatto B, Sissi C. DNA topoisomerase-targeted drugs. In: Demeunynch M, Bailly C, Wilson WD, editors. DNA and RNA binders, vol. 1 from small molecules to drugs. Wiley-VCH; 2002. p. 503-37.
4. Frishman W.H., Sung H.M., Yee H.C., Liu L.L., Keefe D., Einzig A.I., Dutcher J. Cardiovascular toxicity with cancer chemotherapy. Curr. Probl. Cancer. 21:1997;301-330.
5. Krapcho A.P., Landi J.J. Jr., Hacker M.P., McCormack J.J. Synthesis and antineoplastic evaluations of 5,8-bis[(aminoalkyl)amino]-1-azaanthracene-9,10- diones. J. Med. Chem. 28:1985;1124-1126.
6. Krapcho A.P., Petry M.E., Getahun Z., Landi J.J. Jr., Stallman J., Polsenberg J.F., Gallagher C.E., Maresch M.J., Hacker M.P., Giuliani F.C., Beggiolin G., Pezzoni G., Menta E., Manzotti C., Oliva A., Spinelli S., Tognella S. 6,9-Bis[(aminoalkyl)amino]benzo[g]isoquinoline-5,10-diones. A novel class of chromophore-modified antitumor anthracene-9,10-diones: synthesis and antitumor evaluations. J. Med. Chem. 37:1994;828-837.
7. Gandolfi C.A., Beggiolin G., Menta E., Palumbo M., Sissi C., Spinelli S., Johnson F. Chromophore-modified antitumor anthracenediones: synthesis, DNA binding, and cytotoxic activity of 1,4-bis[(aminoalkyl)amino]benzo[g]- phthalazine-5,10-diones. J. Med. Chem. 38:1995;526-536.
8. Faivre S., Raymond E., Boige V., Gatineau M., Buthaut X., Rixe O., Bernareggi A., Camboni G., Armand J.P. A phase I and pharmacokinetic study of the novel aza-anthracenedione compound BBR 2778 in patients with advanced solid malignancies. Clin. Cancer Res. 7:2001;43-50.
9. Borchmann P., Schnell R., Knippertz R., Staak J.O., Camboni G.M., Bernareggi A., Hubel K., Staib P., Schulz A., Diehl V., Engert A. Phase I study of BBR 2778, a new aza-anthracenedione, in advanced or refractory non-Hodgkin's lymphoma. Ann. Oncol. 12:2001;661-667.
10. Dawson L.K., Jodrell D.I., Bowman A., Rye R., Byrne B., Bernareggi A., Camboni G., Smyth J.F. A clinical phase I and pharmacokinetic study of BBR 2778, a novel anthracenedione analogue, administered intravenously, 3 weekly. Eur. J. Cancer. 36:2000;2353-2359.
11. Showalter H.D.H., Johnson J.L., Hoftiezer J.M., Turner W.R., Werbel L.M., Leopold W.R., Shillis J.L., Jackson R.C., Elslager E.F. Anthrapyrazole anticancer agents. Synthesis and structure-activity relationship against murine leukemias. J. Med. Chem. 30:1987;121-131.
12. Talbot D.C., Smith I.E., Mansi J.L., Hudson I., Calvert A.H., Ashley S.E. Anthrapyrazole CI-941: a highly active new agent in the treatment of advanced breast cancer. J. Clin. Oncol. 9:1991;2141-2147.
13. Walsh S.M., Walley W.M., Chandra M., Huan S.D., Veinot J.P. Higginson LAJ, potential carditoxicity with the use of DuP-941: a case report. Can. J. Cardiol. 11:1995;419-422.
14. Krapcho A.P., Menta E. Antitumor aza-anthrapyrazoles. Drugs Fut. 22:1997;641-646.
15. Sissi C., Moro S., Richter S., Gatto B., Menta E., Spinelli S., Krapcho A.P., Zunino F., Palumbo M. DNA-interactive anticancer aza-anthrapyrazoles: biophysical and biochemical studies relevant to the mechanism of action. Mol. Pharmacol. 59:2001;96-103.
16. Krapcho A.P., Menta E., Oliva A., Di Domenico R., Fiocchi L., Maresch E., Gallagher C.E., Hacker M.P., Beggiolin G., Giuliani F.C., Pezzoni G., Spinelli S. Synthesis and antitumor evaluation of 2,5-disubstituted-indazolo[4,3-gh] isoquinoline-6(2H)-ones (9-aza-anthrapyrazoles). J. Med. Chem. 41:1998;5429-5444.
17. Beylin V.G., Colbry N.L., Goel O.P., Haky J.E., Johnson D.R., Kanter G.D., Leeds R.L., Leja B., Lewis E.P., Rithner C.D., Showalter H.D.H., Sercel A.D., Turner W.R., Uhlendorf S.E. Anticancer anthrapyrazoles. Improved synthesis of clinical agent CI-937, CI-941, and piroxantrone hydrochloride. J. Heterocycl. Chem. 26:1989;85-96.
18. Wells R.D., Larson J.E., Grant R.C., Shortle B.E., Cantor C.R. Physicochemical studies on polydeoxyribonucleotides containing defined repeating nucleotide sequences. J. Mol. Biol. 54:1970;465-497.
19. Grant R.C., Harwood S.J., Wells R.D. The synthesis and characterization of poly d(I-C). J. Am. Chem. Soc. 90:1968;4474-4476.
20. Binaschi M., Farinosi R., Borgnetto M.E., Capranico G. In vivo site specificity and human isoenzyme selectivity of two topoisomerase II-poisoning anthracyclines. Cancer Res. 60:2000;3770-3776.
21. Cornarotti M., Tinelli S., Willmore E., Zunino F., Fisher L.M., Austin C.A., Capranico G. Drug sensitivity and sequence specificity of human recombinant DNA topoisomerases IIα (p170) and IIβ (p180). Mol. Pharmacol. 50:1996;1463-1471.
22. McGhee J.D., Von Hippel P.H. Theoretical aspects of DNA-protein interactions. Cooperative and non cooperative binding of large ligands to a one-dimensional homogeneous lattice. J. Mol. Biol. 86:1974;469-489.
23. Chambers C.C., Cramer C.J., Truhlar D.G. A model for aqueous solvation based on class IV atomic charges and first-solvation-shell effects. J. Phys. Chem. 100:1996;16385-16398.
24. Qui D., Shenkin S., Hollinger F.P., Still W.C. The GB/SA continuum model for solvation. A foot analytical method for the calculation of approximate born radii. J. Phys. Chem. 101:1997;3005-3017.
25. Hartley J.A., Reszka K., Zuo E.T., Wilson W.D., Morgan A.R., Lown J.W. Characteristics of the interaction of anthrapyrazole anticancer agents with deoxyribonucleic acids: structural requirements for DNA binding, intercalation, and photosensitization. Mol. Pharmacol. 33:1988;65-71.
26. Denny W.A., Wakelin L.P. Kinetics of the binding of mitoxantrone, ametantrone and analogues to DNA: relationship with binding mode and anti-tumor activity. Anticancer Drug Des. 5:1990;189-200.
27. Lown J.W., Morgan A.R., Yen S.F., Wang Y.T., Wilson W.D. Characteristics of the binding of the anticancer agents mitoxantrone and ametantrone and related structures to deoxyribonucleic acids. Biochemistry. 24:1985;4028-4035.
28. Lyng R., Rodger A., Norden B. The CD of ligand-DNA systems. I. Poly(dG-dC) B-DNA. Biopolymers. 31:1991;1709-1720.
29. Lyng R., Rodger A., Norden B. The CD of ligand-DNA systems. 2. Poly(dA-dT) B-DNA. Biopolymers. 32:1992;1201-1210.
30. Supino R., Polizzi D., Pavesi R., Pratesi G., Guano F., Capranico G., Palumbo M., Sissi C., Richter S., Beggiolin G., Menta E., Pezzoni G., Spinelli S., Torriani D., Carenini N., Del Bo L., Facchinetti F., Tortoreto M., Zunino F. A novel 9-aza-anthrapyrazole effective against prostatic carcinoma xenografts. Oncology. 51:2001;234-242.